CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
Melani Luque(Hospital Universitario Fundación Jiménez Díaz), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz)
Cited by 7
Related Papers
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
|Journal of Clinical Oncology|2005|409
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
|Journal of Clinical Oncology|2003|259